

## 32-4413: Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9

**Alternative Name :** Proprotein Convertase Subtilisin/Kexin Type 9,NARC1,Subtilisin/Kexin-Like Protease PC9,HCHOLA3,LDLCQ1,NARC-1,FH3,PC9,Convertase Subtilisin/Kexin Type 9 Preproprotein,Hypercholesterolemia,Autosomal Dominant 3,Neural Apoptosis Regulated Conv

### Description

Source : HEK 293. PCSK9 Human Recombinant produced in HEK cells is a single, glycosylated, polypeptide chain (Gln31-Gln692) containing a total of 671 amino acids, having a calculated molecular mass of 72.4kDa and fused to a 10 aa His tag at C-Terminus. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) belongs to the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking via regulated or constitutive branches of the secretory pathway. PCSK9 protein goes through an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. PCSK9 is expressed in the liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. PCSK has a role in cholesterol and fatty acid metabolism. PCSK9 gene mutations are linked with autosomal dominant familial hypercholesterolemia.

### Product Info

**Amount :** 10 µg  
**Purification :** Greater than 95.0% as determined by SDS-PAGE.  
**Content :** PCSK9 filtered (0.4µm) solution at a concentration of 0.25mg/ml in phosphate buffered saline and 20 % (w/v) glycerol.  
**Storage condition :** Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.  
**Amino Acid :** QEDEDGDYEE LVLALRSEED GLAEAPEHGT TATFHRC AKD PWRLPGTYVV VLKEETHLSQ SERTARRLQA QAARRGYLTK ILHVFHGLLP GFLVKMSGDL LELALKLPHV DYIEEDSSVF AQSIPWNLER ITPPRYRADE YQPPDGGSLV EVYLLDTSIQ SDHREIEGRV MVTDFENVPE EDGTRFHRQA SKCDSHGTHL AGVVSGRDAG VAKGASMRSL RVLNCQKGT VSGTLIGLEF IRKSQLVQPV GPLVVLLPLA GGYSRVLNAA CQRLARAGVV LVTAAGNFRD DACLYSPASA PEVITVGATN AQDQPVTLGT LGTNFGRCVD LFAPGEDIIG ASSDCSTCFV SQSGTSQAAA HVAGIAAMML SAPELTLAE LRQLIHFS A KDVINEAWFP EDQRVLTPNL VAALPPSTHG AGWQLFCRTV WSAHSGPTRM ATAVARCAPD EELLSCSSFS RSGKRRGERM EAQGGKLVCR AHNAFGGEGV YAIARCCLLP QANCSVHTAP PAEASMGRV HCHQQGHVLT GCSHWEVED LGTHKPPVLR PRGQPNQCVG HREASIHASC CHAPGLECKV KEHGIPAPQE QVTVACEEGW TLTGCSALPG TSHVLGAYAV DNTCVVRSRD VSTTGSTSEG AVTAVAICCR SRHLAQASQE LQHHHHHHHH HH.

